Certain identified information has been excluded from the exhibit because it is both (i) not material and Double asterisks denote omissions. AMENDMENT to Collaboration, Option and license AgreementLicense Agreement • May 14th, 2020 • Ocular Therapeutix, Inc • Pharmaceutical preparations
This Amendment to the Collaboration, Option and License Agreement (the “Amendment”) is entered into and made effective as of May 8, 2020 (the “Amendment Effective Date”) and amends that certain Collaboration, Option and License Agreement dated October 10, 2016 (the “Agreement”), by and between Ocular Therapeutix, Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 36 Crosby Drive, Suite 101, Bedford, Massachusetts 01730 (“Collaborator”) and Regeneron Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of New York with offices at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”). Collaborator and Regeneron are referred to herein individually as a “Party” and collectively as the “Parties”.
